Latest news with #SLE
Medscape
3 days ago
- Health
- Medscape
Flare and Persistently Active Disease Are Common in Lupus
More than 50% of patients with systemic lupus erythematosus (SLE) experienced flare and nearly 50% had persistently active disease, whereas some had persistently active disease without flare. Both conditions were linked to a greater risk for organ damage accrual. METHODOLOGY: Researchers analyzed data of a multinational observational cohort, including 3811 adults with SLE (median age at diagnosis, 29 years; 92.1% women) enrolled between March 2013 and December 2020, to identify the frequency and determinants of flare and persistently active disease. The patients received treatment under standard care conditions and were followed up every 3-6 months, with a median follow-up duration of 2.8 years. The following definitions were used to assess the disease status: Flare : Defined using the Safety of Estrogens in Lupus Erythematosus National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Persistently active disease: A SLEDAI-2000 score ≥ 4 on two or more consecutive visits with an interval of 6 months or less, excluding cases with serologic activity alone Damage accrual: Any increase in the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index Lupus low disease activity state: A SLEDAI- 2000 score ≤ 4, no activity in major organs, no new disease activity since the last assessment, and standard doses of medications A predictive model for flare and persistently active disease was developed and was validated in a subset of patients. TAKEAWAY: Over the follow-up period, 56.2% of patients experienced flare, and 46.9% had persistently active disease; notably, 9.7% experienced persistently active disease without flare, and 37.2% experienced both. Both flare and persistently active disease were associated with an increased risk for damage accrual (adjusted odds ratio [aOR], 1.29; P = .021 and aOR, 1.55; P < .001, respectively). = .021 and aOR, 1.55; < .001, respectively). Predictors of subsequent flare included low gross domestic product in country of residence, smoking, renal activity, arthritis, low complement levels, and the use of mycophenolate mofetil/mycophenolic acid during the first 3 years ( P < .05 for all). Renal activity and time-adjusted mean SLEDAI-2000 score were predictors of persistently active disease ( P < .001 for both). < .05 for all). Renal activity and time-adjusted mean SLEDAI-2000 score were predictors of persistently active disease ( < .001 for both). Achieving a lupus low disease activity state for ≥ 50% of the follow-up time had a significant protective effect against the subsequent development of both conditions. Moreover, the predictive model correctly classified 72.1% of flares (area under the receiver operating characteristic [ROC] curve, 0.74) and 83.8% of persistently active disease (area under the ROC curve, 0.88). IN PRACTICE: 'The high frequency of PAD [persistently active disease] and its negative impact on patient outcomes make a compelling case for its use as a clinically meaningful endpoint,' the authors of the study wrote. 'Our predictive models may help identify patients at high risk of flare or PAD to target for more stringent follow-up and assist in selecting high-risk patients for clinical trials.' SOURCE: This study was led by Yanjie Hao, MD, University of Melbourne and St Vincent's Hospital Melbourne, both in Melbourne, Australia, and Peking University First Hospital in Beijing, China. It was published online on February 26, 2025, in ACR Open Rheumatology . LIMITATIONS: The SLEDAI-2000 score used to define persistently active disease may have omitted several clinical manifestations while potentially overestimating its frequency. The findings suggested an association and not causation. The use of rituximab and belimumab was limited, and information on the use of anifrolumab and ciclosporin was lacking. DISCLOSURES: The Asia Pacific Lupus Collaboration received grants from several sources, including AstraZeneca, Bristol Myers Squibb, and Eli Lilly. One author reported receiving a research scholarship from the University of Melbourne, and another author reported receiving support in part from a research program through the National Research Foundation of Korea. Two other authors reported receiving grants from the National Health and Medical Research Council.
Health Line
4 days ago
- Health
- Health Line
What to Know About Lupus Cystitis
Lupus cystitis is a rare complication of systemic lupus erythematosus (SLE). It can cause symptoms such as increased urination, the sudden need to urinate, pain during urination, and lower abdominal pain. Lupus is an autoimmune condition that can affect different parts of the body. In rare cases, it can affect the urinary system, which may lead to lupus cystitis. Read on to learn more about lupus cystitis, including the causes and symptoms. This article also looks at how doctors diagnose lupus cystitis, the treatment options, and more. What causes lupus cystitis? The exact cause of lupus cystitis is unclear. However, researchers believe that it could happen due to proteins being deposited in the bladder, leading to inflammation and damage in the lining of the bladder. »Learn more: What Causes Lupus? Vs. cystitis Lupus cystitis and cystitis are different conditions. Lupus cystitis likely happens due to inflammation of the bladder, and affects people with the autoimmune condition lupus. Cystitis is a type of urinary tract infection (UTI) that is typically caused by bacteria. According to a 2025 report, doctors sometimes misdiagnose lupus cystitis as a UTI as they can present with similar symptoms. What are the symptoms of lupus cystitis? Lupus cystitis can cause symptoms such as: urinary urgency, or a sudden need to urinate urinary frequency, or urinating more often dysuria, or pain or discomfort when urinating suprapubic pain, or pain in the lower abdomen These symptoms are nonspecific, which means that they can also happen due to other conditions, such as a UTI. How do doctors diagnose lupus cystitis? Lupus cystitis can be difficult to diagnose, as it can resemble other conditions and may be misdiagnosed as a UTI. If you have lupus and symptoms of either condition, it is important to make sure your doctor is aware of the lupus so that they can consider lupus cystitis as a possible diagnosis. In some cases, lupus cystitis may happen before a lupus diagnosis. To assist with reaching an accurate diagnosis, a doctor may begin by performing a physical examination and asking questions about symptoms. They may then order imaging tests such as cystoscopy. It is also usually necessary to perform a bladder biopsy to confirm the diagnosis. What are the treatments for lupus cystitis? Doctors may recommend medications for the treatment of lupus cystitis. Medications they may recommend include the corticosteroids prednisolone and methylprednisolone, as well as mycophenolate mofetil, an immunosuppressive medication. Doctors will administer the medication intravenously. What are the possible complications of lupus cystitis? Lupus cystitis may lead to complications such as bladder fibrosis. Bladder fibrosis refers to scarring of the bladder tissue. This can lead to decreased bladder capacity. Early diagnosis and treatment is essential for helping reduce the likelihood of complications. Contact a doctor as soon as there are concerns about the symptoms of lupus cystitis. How common is lupus cystitis? Lupus cystitis is a rare complication that can occur in people with lupus. It occurs in around 0.5% to 2% of lupus cases. The bottom line Lupus cystitis is a rare complication that can develop in people with systemic lupus erythematosus (SLE). While the exact cause is unclear, it may develop due to proteins depositing in the bladder. Symptoms of lupus cystitis can include increased urinary frequency or urgency, pain when urinating, and lower abdominal pain. As the symptoms can be similar to urinary tract infections (UTIs), the condition can be difficult to diagnose. To assist in diagnosing lupus cystitis, a doctor may order imaging tests such as cystoscopy. Bladder biopsy may also be necessary. Treatments for lupus cystitis may include intravenous corticosteroids, such as prednisolone and methylprednisolone, or the immunosuppressive medication mycophenolate mofetil.
Yahoo
5 days ago
- Health
- Yahoo
GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US
Grant funding will be provided to support national, state, and local non-profit organizations and community-based groups focused on lupus New resources and tools will support implementation of community-led programs designed to improve earlier diagnosis, enhance awareness of and access to evidence-based treatment, and/or advance communication between patients and providers Deadline for proposals is September 1, 2025 PHILADELPHIA, June 16, 2025--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support individuals impacted with lupus, particularly systemic lupus erythematosus (SLE) and lupus nephritis (LN). "Too many people living with lupus face delays in diagnosis and disconnects in care," said Court Horncastle, Senior Vice President at GSK. "With this initiative, we're proud to support the organizations working within local communities to improve diagnosis, access to optimal care, and connection for those impacted by lupus." GSK is seeking proposals for community-driven initiatives aimed at improving earlier diagnosis and recognition of lupus signs and symptoms; enhancing awareness of and access to evidence-based treatment options; and/or advancing communication between patients and providers regarding lupus. GSK is committing up to $1 million USD in grant funding to support national, state, and local non-profit organizations and community-based groups focused on lupus. This program is in addition to existing funding opportunities GSK provides to support the critical work of partner organizations within the lupus ecosystem. GSK recognizes the pivotal leadership demonstrated by these types of groups and the need to sustain their important work as patient advocates. Eligible organizations should respond to the Call for Grant Applications (CGA) with programming that aligns with the Linked by Lupus: Optimal Care Initiative mission to support people impacted by lupus and help create a sustainable lupus community that fosters a sense of belonging, shared understanding, and mutual support among patients and care partners in the US. Grant proposals are due by September 1, 2025 and will be reviewed and approved according to set principles and criteria. To receive the principles and criteria, please email The grant application process is now open on When submitting your request, please use the following format in your project title: Linked by Lupus: [insert your grant title]. GSK will coordinate regular convenings with external stakeholders and harness existing forums to share best practices in addressing health inequities in lupus, empowering public health organizations and communities with actionable models to help bring successful efforts to scale. More information is available at About GSKGSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at Cautionary statement regarding forward-looking statementsGSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q1 Results for 2025. Registered in England & Wales:No. 3888792 Registered Office:79 New Oxford StreetLondonWC1A 1DG View source version on Contacts GSK inquiriesMedia:Tim Foley +44 (0) 20 8047 5502 (London)Dan Smith +44 (0) 20 8047 5502 (London)Kathleen Quinn +1 202 603 5003 (Washington DC)Lyndsay Meyer +1 202 302 4595 (Washington DC) Investor Relations:Constantin Fest +44 (0) 7831 826525 (London)James Dodwell +44 (0) 20 8047 2406 (London)Mick Readey +44 (0) 7990 339653 (London)Steph Mountifield +44 (0) 7796 707505 (London)Jeff McLaughlin +1 215 751 7002 (Philadelphia)Frannie DeFranco +1 215 751 3126 (Philadelphia) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Health
- Yahoo
GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US
Grant funding will be provided to support national, state, and local non-profit organizations and community-based groups focused on lupus New resources and tools will support implementation of community-led programs designed to improve earlier diagnosis, enhance awareness of and access to evidence-based treatment, and/or advance communication between patients and providers Deadline for proposals is September 1, 2025 PHILADELPHIA, June 16, 2025--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support individuals impacted with lupus, particularly systemic lupus erythematosus (SLE) and lupus nephritis (LN). "Too many people living with lupus face delays in diagnosis and disconnects in care," said Court Horncastle, Senior Vice President at GSK. "With this initiative, we're proud to support the organizations working within local communities to improve diagnosis, access to optimal care, and connection for those impacted by lupus." GSK is seeking proposals for community-driven initiatives aimed at improving earlier diagnosis and recognition of lupus signs and symptoms; enhancing awareness of and access to evidence-based treatment options; and/or advancing communication between patients and providers regarding lupus. GSK is committing up to $1 million USD in grant funding to support national, state, and local non-profit organizations and community-based groups focused on lupus. This program is in addition to existing funding opportunities GSK provides to support the critical work of partner organizations within the lupus ecosystem. GSK recognizes the pivotal leadership demonstrated by these types of groups and the need to sustain their important work as patient advocates. Eligible organizations should respond to the Call for Grant Applications (CGA) with programming that aligns with the Linked by Lupus: Optimal Care Initiative mission to support people impacted by lupus and help create a sustainable lupus community that fosters a sense of belonging, shared understanding, and mutual support among patients and care partners in the US. Grant proposals are due by September 1, 2025 and will be reviewed and approved according to set principles and criteria. To receive the principles and criteria, please email The grant application process is now open on When submitting your request, please use the following format in your project title: Linked by Lupus: [insert your grant title]. GSK will coordinate regular convenings with external stakeholders and harness existing forums to share best practices in addressing health inequities in lupus, empowering public health organizations and communities with actionable models to help bring successful efforts to scale. More information is available at About GSKGSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at Cautionary statement regarding forward-looking statementsGSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q1 Results for 2025. Registered in England & Wales:No. 3888792 Registered Office:79 New Oxford StreetLondonWC1A 1DG View source version on Contacts GSK inquiriesMedia:Tim Foley +44 (0) 20 8047 5502 (London)Dan Smith +44 (0) 20 8047 5502 (London)Kathleen Quinn +1 202 603 5003 (Washington DC)Lyndsay Meyer +1 202 302 4595 (Washington DC) Investor Relations:Constantin Fest +44 (0) 7831 826525 (London)James Dodwell +44 (0) 20 8047 2406 (London)Mick Readey +44 (0) 7990 339653 (London)Steph Mountifield +44 (0) 7796 707505 (London)Jeff McLaughlin +1 215 751 7002 (Philadelphia)Frannie DeFranco +1 215 751 3126 (Philadelphia) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
5 days ago
- Health
- Business Wire
GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support individuals impacted with lupus, particularly systemic lupus erythematosus (SLE) and lupus nephritis (LN). 'Too many people living with lupus face delays in diagnosis and disconnects in care,' said Court Horncastle, Senior Vice President at GSK. 'With this initiative, we're proud to support the organizations working within local communities to improve diagnosis, access to optimal care, and connection for those impacted by lupus.' GSK is seeking proposals for community-driven initiatives aimed at improving earlier diagnosis and recognition of lupus signs and symptoms; enhancing awareness of and access to evidence-based treatment options; and/or advancing communication between patients and providers regarding lupus. GSK is committing up to $1 million USD in grant funding to support national, state, and local non-profit organizations and community-based groups focused on lupus. This program is in addition to existing funding opportunities GSK provides to support the critical work of partner organizations within the lupus ecosystem. GSK recognizes the pivotal leadership demonstrated by these types of groups and the need to sustain their important work as patient advocates. Eligible organizations should respond to the Call for Grant Applications (CGA) with programming that aligns with the Linked by Lupus: Optimal Care Initiative mission to support people impacted by lupus and help create a sustainable lupus community that fosters a sense of belonging, shared understanding, and mutual support among patients and care partners in the US. Grant proposals are due by September 1, 2025 and will be reviewed and approved according to set principles and criteria. To receive the principles and criteria, please email The grant application process is now open on When submitting your request, please use the following format in your project title: Linked by Lupus: [insert your grant title]. GSK will coordinate regular convenings with external stakeholders and harness existing forums to share best practices in addressing health inequities in lupus, empowering public health organizations and communities with actionable models to help bring successful efforts to scale. More information is available at About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the 'Risk Factors' section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q1 Results for 2025. Registered in England & Wales: No. 3888792 Registered Office: 79 New Oxford Street London WC1A 1DG
